AU3459697A - Novel pyrimidine compounds and drug compositions - Google Patents

Novel pyrimidine compounds and drug compositions

Info

Publication number
AU3459697A
AU3459697A AU34596/97A AU3459697A AU3459697A AU 3459697 A AU3459697 A AU 3459697A AU 34596/97 A AU34596/97 A AU 34596/97A AU 3459697 A AU3459697 A AU 3459697A AU 3459697 A AU3459697 A AU 3459697A
Authority
AU
Australia
Prior art keywords
pyrimidine compounds
drug compositions
novel pyrimidine
novel
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU34596/97A
Inventor
Yasuhiko Kanda
Yasuyuki Kawanishi
Toshiro Konoike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU3459697A publication Critical patent/AU3459697A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU34596/97A 1996-07-23 1997-07-11 Novel pyrimidine compounds and drug compositions Abandoned AU3459697A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP19301496 1996-07-23
JP8-193014 1996-07-23
PCT/JP1997/002408 WO1998003488A1 (en) 1996-07-23 1997-07-11 Novel pyrimidine compounds and drug compositions

Publications (1)

Publication Number Publication Date
AU3459697A true AU3459697A (en) 1998-02-10

Family

ID=16300761

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34596/97A Abandoned AU3459697A (en) 1996-07-23 1997-07-11 Novel pyrimidine compounds and drug compositions

Country Status (3)

Country Link
JP (1) JP4125787B2 (en)
AU (1) AU3459697A (en)
WO (1) WO1998003488A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
CN1407973A (en) * 1999-12-22 2003-04-02 埃科特莱茵药品有限公司 Butyne diol derivatives
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
CN100537546C (en) * 2002-01-02 2009-09-09 埃科特莱茵药品有限公司 Novel alkansulfonamides as endothelin antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
KR960703901A (en) * 1993-08-19 1996-08-31 로즈 암스트롱 Substituted 2 (5H) furanone, 2 (5H) thiophenone and 2 (5H) pyrrolone derivatives, methods for their preparation and their use as endothelin antagonists (Substituted 2 (5H) Furanone, 2 (5H) Thiophenone and 2 (5H) Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists)

Also Published As

Publication number Publication date
JP4125787B2 (en) 2008-07-30
WO1998003488A1 (en) 1998-01-29

Similar Documents

Publication Publication Date Title
AU1157599A (en) Pyrimidinone compounds and pharmaceutical compositions containing them
AU1618697A (en) Novel compounds and pharmaceutical use thereof
AU4762797A (en) Pharmaceutical compositions
AU6740298A (en) Pharmaceutical composition
AU2967597A (en) Pharmaceutical compositions
AU5136998A (en) Medicinal composition
AU7590096A (en) Drug composition
AU5856898A (en) Heteroarylsulfonamide derivatives and pharmaceutical compositions containing them
AU3777897A (en) Pharmaceutical compositions
AU8107998A (en) Pharmaceutical compositions
AU5317598A (en) Novel pharmaceutical compositions
AU5335798A (en) Stomatic composition
AU8747498A (en) Food-preservative composition
AU7904998A (en) Pharmaceutical composition containing peptichemio
AU2531295A (en) Pharmaceutical composition
AU9343098A (en) Pharmaceutical composition
AU8121998A (en) Composition
AU5326298A (en) Pharmaceutical compositions containing N-sulphonylindoline derivatives
AU8695298A (en) Compounds and uses thereof
AU3460897A (en) Medicinal compositions
AUPP332898A0 (en) Pharmaceutical composition
AU3459697A (en) Novel pyrimidine compounds and drug compositions
AU1098499A (en) Emulsifier-lipid composition
AU4326197A (en) Pharmaceutical compositions
AUPN862596A0 (en) Pharmaceutical compositions